| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2014.58.2320 |
| P8608 | Fatcat ID | release_t5ndjab7iffbdpksfprqkvyofa |
| P932 | PMC publication ID | 4477789 |
| P698 | PubMed publication ID | 25987701 |
| P50 | author | Fabrice Smieliauskas | Q86833680 |
| Thomas J. Smith | Q54102413 | ||
| P2093 | author name string | Daniel M Geynisman | |
| Ronan J Kelly | |||
| Ya-Chen Tina Shih | |||
| P2860 | cites work | Limits on Medicare's ability to control rising spending on cancer drugs | Q83256619 |
| Targeted cancer therapies | Q84334032 | ||
| NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia | Q84823041 | ||
| Drug parity legislation: states, organizations seek to make oral cancer drugs more affordable | Q87146770 | ||
| Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care | Q87305797 | ||
| Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting | Q30492745 | ||
| Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis | Q30560856 | ||
| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts | Q34310173 | ||
| Projections of the cost of cancer care in the United States: 2010-2020. | Q35022830 | ||
| Impact of the 2008-2009 economic recession on screening colonoscopy utilization among the insured | Q36051453 | ||
| Delivering high-quality and affordable care throughout the cancer care continuum | Q37278390 | ||
| The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology | Q38195127 | ||
| Potential approaches to sustainable, long-lasting payment reform in oncology | Q38204969 | ||
| Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia | Q42634744 | ||
| How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment | Q43014207 | ||
| Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective. | Q51222526 | ||
| What is targeted therapy? | Q81498284 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2190-2196 | |
| P577 | publication date | 2015-05-18 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011 | |
| P478 | volume | 33 |
| Q42694880 | Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia |
| Q38614152 | Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. |
| Q51570234 | Association of polymorphisms in translesion synthesis genes with prognosis of advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. |
| Q40101403 | Cancer care cost trends in the United States: 1998 to 2012. |
| Q41246351 | Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. |
| Q99711931 | Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study |
| Q26746976 | Critical care of patients with cancer |
| Q38837677 | Current situation and future usage of anticancer drug databases |
| Q47405286 | Diffusion of Bevacizumab Across Oncology Practices: An Observational Study |
| Q61797308 | Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells |
| Q40156303 | Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. |
| Q54995746 | Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century. |
| Q38403303 | Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications. |
| Q38984073 | Financial Hardships Experienced by Cancer Survivors: A Systematic Review. |
| Q94585285 | Financial hardship in Chinese cancer survivors |
| Q38835979 | Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents, an update (2013-2015). |
| Q47289504 | Influence of Chemotherapy Within 30 Days Before ICU Admission on Mortality in Critically Ill Medical Patients With Cancer |
| Q91988095 | Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value |
| Q37007189 | Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study |
| Q91694213 | Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications |
| Q37350878 | Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy |
| Q55654248 | Mitoxantrone is More Toxic than Doxorubicin in SH-SY5Y Human Cells: A 'Chemobrain' In Vitro Study. |
| Q48296939 | National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study. |
| Q39717218 | New strategies in esophageal carcinoma: promises and problems |
| Q88810858 | Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit |
| Q47221850 | Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws |
| Q36017710 | Patient and interest organizations' views on personalized medicine: a qualitative study |
| Q64087322 | Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, r |
| Q45212989 | Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. |
| Q39156080 | Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries |
| Q38670836 | State insurance mandates and off-label use of chemotherapy. |
| Q90387005 | Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine |
| Q64106342 | The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells |
| Q101059577 | The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States |
| Q92315526 | The impact of pricing strategy on the costs of oral anti-cancer drugs |
| Q90637849 | The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer |
| Q92260629 | The social and economic toll of cancer survivorship: a complex web of financial sacrifice |
| Q50004287 | Use of Charity Financial Assistance for Novel Oral Anticancer Agents. |
Search more.